(Q46011043)

18 December 2017

title

[Socioeconomic relevance of the idiopathic restless legs syndrome (RLS) in Germany: cost-of-illness study]. (English)

1 reference

18 December 2017

main subject

Germany

0 references

socioeconomics

0 references

restless legs syndrome

1 reference

Sandra Nelles

1

1 reference

18 December 2017

Juliane Köberlein

2

1 reference

18 December 2017

Christine Grimm

3

1 reference

18 December 2017

David Pittrow

4

1 reference

18 December 2017

Wilhelm Kirch

5

1 reference

18 December 2017

Reinhard Rychlik

6

1 reference

18 December 2017

language of work or name

German

0 references

publication date

16 May 2009

1 reference

18 December 2017

published in

Medizinische Klinik

1 reference

18 December 2017

volume

104

1 reference

18 December 2017

issue

5

1 reference

18 December 2017

page(s)

363-371

1 reference

18 December 2017

A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms.

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00063-009-1075-X

Restless Legs Syndrome is Associated with DSM-IV Major Depressive Disorder and Panic Disorder in the Community

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00063-009-1075-X

Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study)

21 January 2018

1 reference

12 December 2020

[Effectiveness of echinacin in therapy of chronic recurrent respiratory disease]

1 reference

12 December 2020

[Sleep disorders and sleep-related breathing disorders]

1 reference

12 December 2020

A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome

1 reference

12 December 2020

A better future for patients with restless legs syndrome.

1 reference

12 December 2020

Effect of nonergot dopamine agonists on symptoms of restless legs syndrome.

1 reference

12 December 2020

Augmentation: understanding a key feature of RLS.

1 reference

12 December 2020

One‐year treatment with standard and sustained‐release levodopa: Appropriate long‐term treatment of restless legs syndrome?

1 reference

12 December 2020

Six months treatment of restless legs syndrome with levodopa/benserazide in domiciliary practice

1 reference

12 December 2020

Clinical significance of RLS.

1 reference

12 December 2020

Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial.

1 reference

12 December 2020

Restless legs syndrome prevalence and impact: REST general population study

1 reference

12 December 2020

Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial.

1 reference

12 December 2020

Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study

1 reference

12 December 2020

Restless legs syndrome, periodic limb movements in sleep, and depression

1 reference

12 December 2020

Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study.

1 reference

12 December 2020

Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.

1 reference

12 December 2020

An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.

1 reference

12 December 2020

Evaluating the quality of life of patients with restless legs syndrome.

1 reference

12 December 2020

Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community

1 reference

12 December 2020

Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome

1 reference

12 December 2020

Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries

1 reference

12 December 2020

10.1007/S00063-009-1075-X

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017